OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/18/2026
Back to search
Official data from USPTO
RHYGAZE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RHYGAZE
ST13
US500000079413712Class
5, 42, 44
Filing
79413712
Registration
8155620
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
06/19/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
11/08/2024
Registration date
03/03/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/03/2026
Last transaction
06/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
Basel, CH
Examiner
HUDSON, TAMARA BREE
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
RhyGaze AG
Representatives
James R Menker Holley & Menker, PA
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparationsophthalmologic preparations; biological medical and pharmaceutical preparations for treating ophthalmologic conditionsailmentsdiseases and disorders; Pharmaceutical and medical preparations for treating eye diseases; biological medical and pharmaceutical preparations for treating eye diseases; pharmaceutical and biological preparations for use in cell cultures for medical purposesnucleic acidsprotein arraysprotein conjugatessynthetic peptidesattenuated virusesviral vectors and viral constructions; biological tissue cultures for medical use; biological tissue cultures intended for medical use in the diagnosisprevention and treatment of diseasesin particular eye diseases; biological tissue cultures intended for medical use in gene therapy treatments; pharmaceutical preparations for use in genetic-based therapiesgene therapy preparationsgene-editing preparationsgenome-editing preparationspreparations incorporating CRISPR-based therapeutic agents for the treatment of eye diseases and other medical conditions; biological preparations comprising genetically modified cellsmodified nucleic acidsviral and non-viral vectors for use in gene therapy and genome-editing medical treatments; all of the foregoing excluding preparations or other goods for the treatment of cancer and oncological diseases and disorders
Class 42
Scientific and technological servicesresearch and design services relating to gene therapygenetic-based therapiesgenome-editing technologiesCRISPR technologiesmolecular biologybiotechnologypharmacy and medicine; quality control for others and authentication of data in the field of medical records using blockchain technology; design and development of computers and software; research and development services in the fields of molecular biologybiotechnologypharmacy and medicine; research and development services in the fields of molecular biologybiotechnologypharmacy and medicinein particular in the field of eye diseases; research and development services in the field of medical diagnosticsprophylaxis and therapyin particular gene therapy; research servicesscientific examination and research of compounds and components intended for therapeutic or diagnostic usein particular intended for use in relation to eye diseases; research services in the field of gene therapy; research and development in the fields of genome editingCRISPR-based technologiesgenetic-engineering tools for medical and therapeutic use; scientific research for developing protocolsfor technical planningfor providing advice in the fields of molecular biologybiotechnology and pharmacyin particular intended for use in the field of ocular diseases and gene therapies
Class 44
Medical services; medical servicesnamely medical diagnosis through molecular biologygenetic engineering and biotechnology methodsin particular in the field of eye diseases; therapy servicesin particular gene therapy for medical treatment purposes
Publications
History of USPTO decisions and trademark events.
24 publications found
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/03/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/01/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/31/2026
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/06/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/13/2026
PUBO
PUBLISHED FOR OPPOSITION
01/13/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/07/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/16/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/15/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/15/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/15/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
09/26/2025
RFNT
REFUSAL PROCESSED BY IB
07/12/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/20/2025
RFRR
REFUSAL PROCESSED BY MPU
06/20/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/17/2025
CNRT
NON-FINAL ACTION WRITTEN
04/16/2025
DOCK
ASSIGNED TO EXAMINER
04/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/03/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/02/2025
Continuous trademark protection
Get notified about every new filing that threatens RHYGAZE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.